title: Serum tumor necrosis factor alpha receptors p55/p75 ratio and ovarian cancer detection.
abstract: OBJECTIVE
  Early ovarian cancer detection is still very difficult and patients are mostly in advanced stages, with obvious influence on poor prognosis.
  
  
  METHODS
  Fifty-one ovarian cancer patients and 16 healthy controls had the serum concentrations of TNF alpha receptor p55, p75 and CA-125 measured prospectively and preoperatively.
  
  
  RESULTS
  Mean concentrations of TNF alpha receptor p55, p75 and CA-125 in patients with ovarian cancer were higher than in controls. The ratios of p55 and p75 receptor in ovarian cancer and controls were 0.73+/-0.38 and 0.55+/-0.06 respectively. The areas under ROC curve in detecting malignancy (all FIGO stages) were 0.73, 0.65, 0.88 and 0.85 for p55, p75, p55/p75 ratio and CA-125 respectively. The areas under ROC curve in detecting stage I of ovarian cancer were 0.52, 0.60, 0.84 and 0.66 for p55, p75, p55/p75 ratio and CA-125 respectively.
  
  
  CONCLUSIONS
  Serum TNF alpha p55/p75 ratio showed promising value in ovarian cancer detection.
authors.affiliation: Department of Mother's and Child's Health, Karol-Marcinkowski University of Medical Sciences, Polna St 33, 60-535 Poznan, Poland. parzymsk@gpsk.am.poznan.pl
authors.forename: P
authors.initials: P
authors.lastname: Rzymski
authors.forename: T
authors.initials: T
authors.lastname: Opala
authors.forename: M
authors.initials: M
authors.lastname: Wilczak
authors.forename: J
authors.initials: J
authors.lastname: Woźniak
authors.forename: S
authors.initials: S
authors.lastname: Sajdak
mesh_terms: D018394:CA-125 Antigen / Q000097:blood; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000175:diagnosis*; D011446:Prospective Studies; D012372:ROC Curve; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood*; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000097:blood*
chemical_list: D018394:CA-125 Antigen; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II